SOAGY Stock, Sartorius AG ADR (Representing Preference Share) Information

Sartorius AG is the leading provider of biopharmaceutical fermentation and fluid management. As of 2022, the bioprocess division contributes about 80% to total revenue and the lab division the remaining 20%. The bioprocess division is traded as a separate company, Sartorius Stedim Biotech. Sartorius AG has a 74% ownership of this subsidiary with 85% voting control. In addition to biomanufacturing equipment and consumables, Sartorius offers a wide range of products for general lab use, such as scales, pipettes, and filtration equipment. The business is geographically diverse, with revenue across Europe, the Middle East, and Africa (37% of 2022 sales), the Americas (37%), and Asia-Pacific (26%). Sartorius employs over 15,000 people and has operations in more than 30 countries.